Bristol-Myers Squibb's Multi-Faceted Upside Seeking Alpha Its products under Phase III clinical trials include Eliquis, to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Nulojix to prevent solid organ transplant rejection; Brivanib to block the VEGF and the FGF ... |
